Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
Main objective : Phase 1b: To determine the recommended dose for the Phase 2 portion of this trial for patients with advanced hepatocellular cancer (HCC) with no other standard curative or palliative therapeutic option. Phase 2: To estimate the time to progression (TTP) for patients with advanced HCC who have received LY2181308.
Critère d'inclusion
- Hepatocellular carcinoma (HCC)